Visceral Leishmaniasis Treatment Receives Orphan Drug Status

3 October 2010 (Last Updated October 3rd, 2010 18:30)

iCo Therapeutics has been granted orphan drug designation by the US Food and Drug Administration for iCo-009, an oral formulation of Amphotericin B for the treatment of visceral leishmaniasis. Amphotericin B, a powerful anti-parasitic and anti-fungal agent, is only approved for use in

iCo Therapeutics has been granted orphan drug designation by the US Food and Drug Administration for iCo-009, an oral formulation of Amphotericin B for the treatment of visceral leishmaniasis.

Amphotericin B, a powerful anti-parasitic and anti-fungal agent, is only approved for use in intravenous formulations at present.

Visceral leishmaniasis is a parasitic disease that affects about 12 million people worldwide. Around 500,000 new infections are reported annually.